Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Golan resident convicted of spying for Iran after passing tank movement, missile-impact data - 26 Tire Brands Reasonable for Seniors
- 3'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 4Trump administration plan to reduce access to some student loans angers nurses, health care groups
- 5How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt'
- What we know about Renee Nicole Good, the woman who was killed by an ICE officer in Minneapolis
- Change Your Skincare: 10 Inventive Magnificence Gadgets
- Building a Maintainable Closet: Individual Excursions in Moral Style
- Federal judge upholds Hawaii's new climate change tax on cruise passengers
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it.
- German Court Rejects Bid To Force BMW and Mercedes-Benz To Stop Selling New Combustion-Engine Cars After 2030
- Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz
- Russia earning billions from Hormuz blockade, German trade body says
